• In early June 2026, Stryker launched TPX HD, a premium small bone power tool designed to enhance power, control and ergonomics in complex orthopaedic, minimally invasive and oral maxillofacial procedures, featuring a tapered attachment for better visibility, improved heat management and a shorter, more ergonomic handpiece.
• The TPX HD launch adds a high-performance small bone solution to Stryker’s broader surgical ecosystem, reinforcing its focus on advanced hardware integrated with software control and robotics-enabled workflows.
• We’ll now examine how this new TPX HD platform, alongside Stryker’s robotics and international momentum, may influence its investment narrative.

Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

Stryker Investment Narrative Recap

To own Stryker, you need to believe in long term demand for advanced surgical solutions supported by a deep product pipeline and global reach. The TPX HD launch fits that thesis but does not materially change near term catalysts, which still center on robotics adoption and international expansion. The biggest current risk remains operational pressures such as supply chain constraints and cost inflation, which can weigh on margins even when demand and innovation look solid.

The TPX HD debut is most directly connected to Stryker’s broader Mako and SmartHospital ecosystems, where hardware, software and robotics work together to support complex orthopaedic procedures. As Mako installations and applications expand and new tools like TPX HD plug into the same consoles and workflows, the company’s ability to deepen account penetration and support higher value procedures becomes an important part of the near term narrative.

But while these launches are encouraging, investors should also be aware of how persistent supply chain pressures could still affect...

Stryker's narrative projects $32.6 billion revenue and $6.5 billion earnings by 2029. This requires 8.8% yearly revenue growth and a roughly $3.2 billion earnings increase from $3.3 billion today.

Uncover how Stryker's forecasts yield a $389.24 fair value, a 25% upside to its current price.

Exploring Other Perspectives

Six members of the Simply Wall St Community currently see Stryker’s fair value between US$340.49 and US$389.24, highlighting a fairly tight but optimistic range of views. Against that backdrop, ongoing concerns about supply chain disruptions and cost pressures give you a concrete reason to compare these community estimates with your own expectations for Stryker’s operating performance over time.

Explore 6 other fair value estimates on Stryker - why the stock might be worth as much as 25% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Stryker research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Stryker research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Stryker's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.
• Find 44 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.